BioCryst Pharmaceuticals, Inc. (BCRX)
After hours:
| Previous Close | 4.4800 |
| Open | 4.5900 |
| Bid | 4.4100 x 300 |
| Ask | 4.4400 x 1000 |
| Day's Range | 4.4200 - 4.6700 |
| 52 Week Range | 4.0300 - 8.9600 |
| Volume | |
| Avg. Volume | 3,257,850 |
| Market Cap | 918.173M |
| Beta (5Y Monthly) | 1.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 79,575 shares, and restricted stock units (RSUs) covering an aggregate of 42,400 shares, of BioCryst common stock. The options and RSUs were granted as of April 30, 2024, as inducements material to each employee entering into employmen
- GlobeNewswire
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live
- GlobeNewswire
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “We are excited to announce that ORLADEYO is now approved in the region’s largest market, following the positive regulatory decisions w
